The underlying mechanism may involve the downregulation of CYP17 and AR mRNA and protein expression.<h4>Conclusion</h4>This meta-analysis provides robust evidence supporting the therapeutic efficacy of cryptotanshinone in PCOS. The gene discussed is CYP17A1; the disease is polycystic ovary syndrome.